Clinical Trial Information Disclosure
Our Corporate Commitments
Daiichi Sankyo is committed to the appropriate disclosure of information from its clinical trials. We believe that making protocols information and clinical trial data available to researchers, health care professionals, patients, academicians and others, in appropriate formats, advances science and medicine. These interactions hold promise for the improvement of public health, increased knowledge and deeper trust in pharmaceutical medicines.
As such, Daiichi Sankyo discloses information from our clinical trials through registration and postings on widely accepted public clinical trial registries, in line with our corporate commitments as well as international and national regulatory requirements and disclosure norms established by global and regional pharmaceutical industry associations.
About This Website
Welcome to the Global Clinical Trials Information Disclosure Website of Daiichi Sankyo Group of Companies.
The site contains details on our corporate clinical trial disclosure policy and commitments and access to information on clinical trial protocols, study results, and plain (lay) language study results summaries.
Clinical Trial Protocols & Results Disclosure
Phase I to IV clinical trials are disclosed in Clinical Trial Registries accessible to the public free of charge in line with applicable regulations. Each registry contains adequate trial information to inform prospective clinical trial volunteers, health care practitioners and the general public of the clinical trial title, design, identification / registration number, description and purpose, medical condition or disease being studied, key eligibility criteria, recruitment status, trial sites and contact for information on enrolment.
Clinical Trial Data and Documents Sharing
In addition to routinely publishing clinical research in scientific journals and collaborating with academic researchers, Daiichi Sankyo also complies with applicable regulations and the principles set forth by the European Federation of Pharmaceutical Industries Association (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) to responsibly share clinical trial data upon formal request and approval by an independent review panel.
Contact us using the Inquiry Form if you have any other inquiries related to our clinical trial. Please note that depending on the nature of the inquiry, we may not be able to respond.
Do not use the Inquiry Form to report events presenting an immediate threat to life or property. Reports submitted through this service may not receive an immediate response. If you require emergency assistance, please contact your local authorities.
In case you wish to report an adverse drug reaction, please contact the Daiichi Sankyo affiliate in your home country.